Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes Five RNAi-Related Patent Applications: Oct 23, 2008

Title: RNA Interference-Mediated Inhibition of Gene Expression Using Short Interfering Nucleic Acid
Number: 20080249294
Filed: Sept. 6, 2007
Lead Inventor: Peter Haeberli, Sirna Therapeutics (Merck)
“This invention relates to compounds, compositions, and methods useful for modulating gene expression using short interfering nucleic acid molecules,” the patent application’s abstract states. “In particular, the … invention features small nucleic acid molecules, such as short interfering nucleic acid … and methods used to modulate the expression of genes, such as expressed pseudogenes associated with the maintenance or development of diseases, disorders, traits, and conditions in a subject or organism. The invention also provides small nucleic acid molecules with reduced or attenuated immunostimulatory properties and methods for designing and synthesizing such small nucleic acid molecules having improved toxicologic properties while retaining RNAi activity.”

Title: Lentiviral Vectors and Their Use
Number: 20080254008
Filed: Feb. 16, 2006 PCT Filed: Feb. 16, 2006
Lead Inventor: Boro Dropulic, Lentigen
According to the patent application’s abstract, the invention “relates to lentiviral vectors for gene therapy, cancer treatment, producing recombinant proteins, such as antibodies and vaccines, and other therapeutic purposes. Novel lentiviral vectors are disclosed, e.g., comprising helper sequences in opposite orientations and/or minimally functional LTR sequences, which can be used to prepare high efficiency transduction vectors. Vectors are also designed to express silencing RNA and antisense polynucleotides.”

Title: Predicting Post-Treatment Survival in Cancer Patients with microRNAs
Number: 20080254473
Filed: April 9, 2008
Lead Inventor: Jian-Wei Chen, National Chung-Hsing University
This invention, the patent application’s abstract states, “provides a method for predicting the post-treatment survival prospect of a cancer patient based on the expression level(s) of microRNAs hsa-miR137, hsa-miR372, hsa-miR182, hsa-miR221, and hsa-let-7a.”

Title: Small Interfering RNA Molecules Against Ribonucleotide Reductase and Uses Thereof
Number: 20080255065
Filed: Aug. 8, 2005 PCT Filed: Aug. 8, 2005
Lead Inventor: Aiping Young, Genesense Technologies
The patent application, its abstract states, claims “small interfering RNA molecules that target a mammalian ribonucleotide reductase gene, and which are capable of inhibiting the expression of their target gene. …The siRNA molecules of the invention are capable of attenuating neoplastic cell growth and/or proliferation in vitro and in vivo and, therefore, can be used to attenuate the growth and/or metastasis of various types of mammalian cancers.”

Title: iRNA Agents Targeting CCR5-Expressing Cells and Uses Thereof
Number: 20080255345
Filed: Nov. 21, 2007
Lead Inventor: Muthiah Manoharan, Alnylam Pharmaceuticals
“The invention relates to iRNA agents that preferably include a modification that targets CC chemokine receptor 5,” the patent application’s abstract states. “The invention also relates to methods of making and using such modified iRNA agents.”

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.